A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients
Status:
RECRUITING
Trial end date:
2026-10-18
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the efficacy and safety of venetoclax combined with the CACAG regimen with the traditional "3+7" regimen in the treatment of newly diagnosed intermediate- or high-risk acute myeloid leukemia (AML).
Phase:
PHASE2
Details
Lead Sponsor:
Chinese PLA General Hospital
Collaborators:
940 Hospital of the People's Liberation Army Joint Logistic Support Force Chinese People's Liberation Army Air Force General Hospital First Affiliated Hospital of Harbin Medical University The 960th Hospital of Joint Logistics Support Force of Chinese People's Liberation Army the First People's Hospital of Jining The General Hospital of Western Theater Command Yantai Yuhuangding Hospital